Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison Between Monoclonal Antibody CD20 Treatment (Rituximab (mabthera))and General Corticotherapy Treatment in Patients With Pemphigus

Trial Profile

Comparison Between Monoclonal Antibody CD20 Treatment (Rituximab (mabthera))and General Corticotherapy Treatment in Patients With Pemphigus

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2018

At a glance

  • Drugs Rituximab (Primary) ; Corticosteroids
  • Indications Pemphigus; Pemphigus vulgaris
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Jun 2018 According to the Roche media release, the US Food and Drug Administration (FDA) has approved MabThera/Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris.
    • 14 Feb 2018 According to a Genentech media release, U.S. Food and Drug Administration (FDA) has accepted Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of Rituxan (rituximab) for the treatment of pemphigus vulgaris (PV). The sBLA submission was based on the data from this trial.
    • 13 Jun 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top